No Data
No Data
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Aclaris Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Aclaris' Cash, Cash Equivalents And Marketable Securities Of $149.9M As Of June 30, 2024 And $26.5M From Sale Of Olumiant Royalties And Milestones Will Be Sufficient To Fund Its Operations Into 2028
Express News | Aclaris Therapeutics Q2 2024 GAAP EPS $(0.15) Beats $(0.20) Estimate, Sales $2.766M Beat $1.818M Estimate